These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8919060)

  • 21. The activation of adenylate cyclase by pituitary adenylate cyclase activating polypeptide (PACAP) via helodermin-preferring VIP receptors in human SUP-T1 lymphoblastic membranes.
    Gourlet P; De Neef P; Woussen-Colle MC; Vandermeers A; Vandermeers-Piret MC; Robberecht P; Christophe J
    Biochim Biophys Acta; 1991 Jul; 1066(2):245-51. PubMed ID: 1649637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pituitary adenylate cyclase activating polypeptide receptors are present on small cell lung cancer cells.
    Moody TW; Zia F; Makheja A
    Peptides; 1993; 14(2):241-6. PubMed ID: 8387187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs.
    Rawlings SR; Piuz I; Schlegel W; Bockaert J; Journot L
    Endocrinology; 1995 May; 136(5):2088-98. PubMed ID: 7720658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maxadilan specifically interacts with PAC1 receptor, which is a dominant form of PACAP/VIP family receptors in cultured rat cortical neurons.
    Tatsuno I; Uchida D; Tanaka T; Saeki N; Hirai A; Saito Y; Moro O; Tajima M
    Brain Res; 2001 Jan; 889(1-2):138-48. PubMed ID: 11166697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
    Gourlet P; Vandermeers A; Van Rampelbergh J; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
    Ann N Y Acad Sci; 1998 Dec; 865():247-52. PubMed ID: 9928018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maxadilan is a specific agonist and its deleted peptide (M65) is a specific antagonist for PACAP type 1 receptor.
    Uchida D; Tatsuno I; Tanaka T; Hirai A; Saito Y; Moro O; Tajima M
    Ann N Y Acad Sci; 1998 Dec; 865():253-8. PubMed ID: 9928019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
    Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. C-terminally shortened pituitary adenylate cyclase-activating peptides (PACAP) discriminate PACAP I, PACAP II-VIP1 and PACAP II-VIP2 recombinant receptors.
    Gourlet P; Vandermeers A; Vandermeers-Piret MC; Rathé J; De Neef P; Robberecht P
    Regul Pept; 1996 Apr; 62(2-3):125-30. PubMed ID: 8795075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of introduction of an arginine16 in VIP, PACAP and secretin on ligand affinity for the receptors.
    Gourlet P; Vandermeers A; Vandermeers-Piret MC; De Neef P; Waelbroeck M; Robberecht P
    Biochim Biophys Acta; 1996 Dec; 1314(3):267-73. PubMed ID: 8982281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors.
    Gourlet P; Vilardaga JP; De Neef P; Waelbroeck M; Vandermeers A; Robberecht P
    Peptides; 1996; 17(5):825-9. PubMed ID: 8844773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Presence of highly selective receptors for PACAP (pituitary adenylate cyclase activating peptide) in membranes from the rat pancreatic acinar cell line AR 4-2J.
    Buscail L; Gourlet P; Cauvin A; De Neef P; Gossen D; Arimura A; Miyata A; Coy DH; Robberecht P; Christophe J
    FEBS Lett; 1990 Mar; 262(1):77-81. PubMed ID: 2156735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific antibody recognition of rat pituitary adenylate cyclase activating polypeptide receptors.
    Li M; Shioda S; Somogyvári-Vigh A; Onda H; Arimura A
    Endocrine; 1997 Oct; 7(2):183-90. PubMed ID: 9549044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.
    Jamen F; Puech R; Bockaert J; Brabet P; Bertrand G
    Endocrinology; 2002 Apr; 143(4):1253-9. PubMed ID: 11897681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pituitary adenylate cyclase-activating peptide stimulates acute progesterone production in rat granulosa/Lutein cells via two receptor subtypes.
    Gräs S; Hedetoft C; Pedersen SH; Fahrenkrug J
    Biol Reprod; 2000 Jul; 63(1):206-12. PubMed ID: 10859261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural characterization of PACAP receptors on rat liver plasma membranes.
    Nguyen TD; Heintz GG; Wolfe MS
    Am J Physiol; 1993 Nov; 265(5 Pt 1):G811-8. PubMed ID: 8238511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclic lactam analogues of ovine pituitary adenylate cyclase activating polypeptide (PACAP): discovery of potent type II receptor antagonists.
    Bitar KG; Somogyvari-Vigh A; Coy DH
    Peptides; 1994; 15(3):461-6. PubMed ID: 7937320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antagonistic properties are shifted back to agonistic properties by further N-terminal shortening of pituitary adenylate-cyclase-activating peptides in human neuroblastoma NB-OK-1 cell membranes.
    Vandermeers A; Vandenborre S; Hou X; de Neef P; Robberecht P; Vandermeers-Piret MC; Christophe J
    Eur J Biochem; 1992 Sep; 208(3):815-9. PubMed ID: 1327769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors.
    Juarranz MG; Bolaños O; Gutiérrez-Cañas I; Lerner EA; Robberecht P; Carmena MJ; Prieto JC; Rodríguez-Henche N
    Cell Signal; 2001 Dec; 13(12):887-94. PubMed ID: 11728828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. II: Effects of the pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide.
    Aoki Y; Iwasaki Y; Katahira M; Oiso Y; Saito H
    Endocrinology; 1997 May; 138(5):1930-4. PubMed ID: 9112389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.